Back to discover
Disease

Ventricular Dysfunction

Late-stage therapeutic developmentEmerging research
MeSHVentricular Dysfunction
1
Publications
21
Clinical trials
2017
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q2 2028.
Upcoming Milestones
Major developments
Major clinical milestoneHigh impact
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Primary completion2026-10-12
Upcoming trial readoutImportant
Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial
Results expected Q2 20282026-06-25
Clinical Milestones4View
Results expected 1
Recently completed 1
Other updates 2
Activity timeline4

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Dronedaroneapproved

Original application approval — Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in… (2009)

Clinical trials

16 sponsors · 1 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
21
All trials
6
Active
10
Late-stage
6
Completed
Late-stage studies

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

Randomised Placebo Controlled Clinical Trial of Efficacy of MYOcardial Protection in Patients With Postacute inFLAMmatory Cardiac involvEment Due to COVID-19

Phase 3 · Active, not recruiting · Valentina Puentmann

Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes

Phase 2/3 · Recruiting · University of Sao Paulo

Peripheral Low Dose Systemic Thrombolysis Versus Catheter Directed Acoustic Pulse Thrombolysis for Treatment of Submassive Pulmonary Embolism

Phase 4 · Active, not recruiting · Northwell Health

Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C

Phase 4 · Completed · Asan Medical Center

Perioperative High-dose Selenium Supplementation in Patients With Left Ventricular Assist Device - a Double Blinded Randomised Controlled Trial

Phase 3 · Completed · RWTH Aachen University
Recently completed

Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C

Phase 4 · Completed · Asan Medical Center

Perioperative High-dose Selenium Supplementation in Patients With Left Ventricular Assist Device - a Double Blinded Randomised Controlled Trial

Phase 3 · Completed · RWTH Aachen University

A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.

Phase 2 · Completed · Joshua M Hare

Proof of Concept Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

Phase 4 · Completed · Boston University

A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.

Phase 1/2 · Completed · University of Miami

Transplantation in Myocardial Infarction Evaluation (TIME) Protocol: A Phase II, Randomized, Controlled, Double-Blind Trial Evaluating the Effect of Timing on the Administration of Bone Marrow Mononuclear Cells (BMMNCs) Versus Placebo in Patients With Acute Myocardial Infarction

Phase 2 · Completed · The University of Texas Health Science Center, Houston

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2009emaOriginal application approval — Dronedarone· Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered. Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 paper

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Leading journals1
  • Circulation1
Leading researchers5
  • Abd El Aziz M1
  • Cavender MA1
  • Drucker DJ1
  • Meier JJ1
  • Nauck MA1
Affiliations (unnormalised)1
  • From Diabetes Center Bochum-Hattingen1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A condition in which HEART VENTRICLES exhibit impaired function.

Identifiers
MeSHVentricular Dysfunction
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.